Close
FINDING CURES TOGETHER<sup>SM</sup>

AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

​Program 

Saturday, Oct. 26, 2019

Sunday, Oct. 27, 2019

Monday, Oct. 28, 2019

Tuesday, Oct. 29, 2019

Wednesday, Oct. 30, 2019



Saturday, Oct. 26, 2019

Educational Session: Targeting Molecular Subtypes: Successes and Failures
Session Cochairs: Elizabeth Fox, Children’s Hospital of Pennsylvania, Philadelphia, Pennsylvania, and Jaap Verweij, Erasmus University Medical Center, Rotterdam, The Netherlands
3-4:45 p.m.

Successes and failures of targeted drug development in sarcomas
Jaap Verweij

Successes and failures of targeted drug development in pediatric tumors
Elizabeth Fox

Commonalities in successful target selection for drug development
Michael C. Heinrich, Oregon Health and Science University, Portland, Oregon

Panel Discussion


Welcome and Opening Remarks
5-5:10 p.m.


Keynote Session
5:15-7 p.m.

Introduction
Emiliano Calvo, START Madrid, Hospital de Madrid Norte Sanchinarro, Madrid, Spain

Title to be announced
George Coukos, University of Lausanne, Lausanne, Switzerland

Introduction
William R. Sellers, Broad Institute of MIT and Harvard, Cambridge, Massachusetts

Title to be announced
Benjamin L. Ebert, Brigham and Women’s Hospital, Boston, Massachusetts


Opening Reception
7-8:30 p.m.




Sunday, Oct. 27, 2019

Continental Breakfast
7-8 a.m.


Plenary Session 1: The Landscape of CAR-T Therapeutics
Session Cochairs: Hermann Einsele, University Hospital Wurzburg, Wurzburg, Germany, and Crystal L. Mackall, Stanford University School of Medicine, Stanford, California
8-9:45 a.m.

Title to be announced
Hermann Einsele

Title to be announced
Crystal L. Mackal

Additional speaker to be announced

Panel Discussion


Break
9:45-10 a.m.


Plenary Session 2: From Glues to ‘TACs: Redirecting Cellular Protein Degradation
Session Cochairs: Rajesh Chopra, The Institute of Cancer Research, London, United Kingdom, and Nathanael S. Gray, Dana-Farber Cancer Institute, Boston, Massachusetts
10-11:45 a.m.

Title to be announced
Nathanael S. Gray

Title to be announced
Nicolas Thomä, Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland

Title to be announced
Rajesh Chopra

Panel Discussion


Spotlight on Proffered Papers 1
Session Chair: William R. Sellers, Broad Institute of MIT and Harvard, Cambridge, Massachusetts
11:50 a.m.-12:20 p.m.


Poster Session A / Exhibit Show

12:30-4 p.m.


AACR Chemistry in Cancer Research (CICR) Working Group Town Hall

Session Chair: Andrew J. Phillips, C4 Therapeutics, Watertown, Massachusetts

2:30-3:30 p.m.


Concurrent Sessions 1-3

4:15-6 p.m.

Concurrent Session 1: CAR-T and Directed T-cell Therapy: Advancing Beyond B-ALL
Session Cochairs: Ravi A. Madan, National Cancer Institute, Bethesda, Maryland, and Victor Moreno, START Madrid, Hospital Fundación Jiménez Díaz, Madrid, Spain

CAR-T and directed T-cell therapy: Where are we right now?
Victor Moreno

T cell receptor gene therapy for a public neoantigen derived from mutated PIK3CA, a dominant driver oncogene in breast and endometrial cancers
Smita Chandran, Memorial Sloan Kettering Cancer Center, New York, New York

Maximizing the potential of bispecific antibodies for cancer drug development
Paul W.H.I. Parren, Leiden University Medical Center, Leiden, Netherlands

Panel Discussion


Concurrent Session 2: Epigenetics and Targeting Transcription

Session Cochair: Daniel S. Peeper, Netherlands Cancer Institute, Amsterdam, The Netherlands

Title to be announced
Daniel S. Peeper

Additional speakers to be announced

Panel Discussion


Concurrent Session 3: Unveiling the Landscape of Synthetic Lethal or Context Dependent Targets

Session Cochairs: W. Nicholas Haining, Merck & Company, Boston, Massachusetts, and William R. Sellers, Broad Institute of MIT and Harvard, Cambridge, Massachusetts

Title to be announced
William R. Sellers

Title to be announced
Mathew Garnett, Wellcome Trust Sanger Institute, Cambridge, England

Title to be announced
W. Nicholas Haining

Panel Discussion


Evening Off / Dinner on Own
6 p.m.




Monday, Oct. 28, 2019

Continental Breakfast
7-8 a.m.


Plenary Session 3: Targeting DNA Repair, PARP, and Beyond
Session Cochairs: Johann S. de Bono, The Institute of Cancer Research, London, United Kingdom, and Daniel Durocher, Lunenfeld-Tanenbaum Research Institute, Toronto, ON, Canada
8-9:45 a.m.

Title to be announced
Johann S. de Bono

Exploiting DNA replication stress for cancer therapies
Thanos Halazonetis, University of Geneva, Geneva, Switzerland

Navigating gene-gene and drug-gene interaction landscapes underpinning the DNA damage response
Daniel Durocher

Panel Discussion


Break
9:45-10 a.m.


Plenary Session 4: The Role of Liquid Biopsies in Guiding Cancer Therapeutics: Detection, Response Monitoring, and Resistance
Session Cochairs: Jennifer C. Jones, National Cancer Institute, Bethesda, Maryland, and Martijn P.J.K. Lolkema, Erasmus University Medical Center, Rotterdam, The Netherlands
10-11:45 a.m.

Title to be announced
Martijn P.J.K. Lolkema

Title to be announced
Jennifer C. Jones

Additional speaker to be announced

Panel Discussion


Spotlight on Proffered Papers 2
Session Chair: James L. Gulley, National Cancer Institute, Bethesda, Maryland
11:50 a.m.-12:20 p.m.


Poster Session B / Exhibit Show
12:30-4 p.m.


Concurrent Sessions 4-6
4:15-6 p.m.

Concurrent Session 4: Targeting the Innate Immune System

Session Cochair: Richard W. Childs, National Heart, Lung, and Blood Institute, Bethesda, Maryland

Title to be announced
Christian M. Capitini, University of Wisconsin, Madison, Wisconsin

Title to be announced
Richard W. Childs

Additional speaker to be announced

Panel Discussion


Concurrent Session 5: Targeting the RAS/MAP Kinase Pathway
Session Cochairs: Shiva Malek, Genentech, Inc., South San Francisco, California, and Ruth Plummer, Northern Institute for Cancer Research, Newcastle, United Kingdom

Session Overview
Ruth Plummer

Discovery and early development of MRTX849: A mutation-selective KRASG12C inhibitor
James Christensen, Mirati Therapeutics, San Diego, California

Next generation strategies to overcome adaptive resistance to MAPK-directed therapies
Poulikos I. Poulikakos, Icahn School of Medicine at Mount Sinai, New York, New York

Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS-SOS1 interaction
Benjamin Bader, Bayer AG, Leverkusen, Germany

Title to be announced
Shiva Malek

Panel Discussion

Concurrent Session 6: The Genomic Landscape of Cancer and the Evolution of Tumor Heterogeneity
Session Cochairs: Himisha Beltran, Dana-Farber Cancer Institute, Boston, Massachusetts, and Nicholas McGranahan, University College London, London, United Kingdom

Lineage plasticity and the neuroendocrine phenotype as a resistance mechanism in prostate cancer
Himisha Beltran

Title to be announced
Dan Landau, Weill Cornell Medicine, New York, New York

Title to be announced
Nicholas McGranahan

Panel Discussion


Evening Off / Dinner on Own
6 p.m.


AACR Women in Cancer Research (WICR) Anniversary Session
6:30-8:30 p.m.




Tuesday, Oct. 29, 2019

Continental Breakfast
7-8 a.m.


Plenary Session 5: Immuno-Oncology
Session Cochairs: Emiliano Calvo, START Madrid, Hospital de Madrid Norte Sanchinarro, Madrid, Spain, and James L. Gulley, National Cancer Institute, Bethesda, Maryland
8-9:45 a.m.

Identification of genes and pathways of immune resistance to IO via analysis of neoadjuvant treatment with anti-PD-1
Drew M. Pardoll, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland

Title to be announced
Emiliano Calvo

Additional speaker to be announced

Panel Discussion


Break
9:45-10 a.m.


Plenary Session 6: Frontiers in Small-Molecule Drug Discovery
Session Cochairs: William R. Sellers, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, and Paul Workman, The Institute of Cancer Research, London, United Kingdom
10-11:45 a.m.

Discovery of BI-3406: A potent and selective SOS1::KRAS inhibitor as an effective approach against KRAS-driven tumors
Marco H. Hofmann, Boehringer Ingelheim, Vienna, Austria

ALK2 open drug discovery: A development path from genes to affordable medicines in DIPG
Aled Edwards, Structural Genomics Consortium, Toronto, ON, Canada

Inhibitors of the HSF1 stress pathway derived from phenotypic screening: Targeting non-oncogene addiction in ovarian and other cancers
Paul Workman

Panel Discussion


Spotlight on Proffered Papers 3
Session Chair: Emiliano Calvo, START Madrid, Hospital de Madrid Norte Sanchinarro, Madrid, Spain
11:50 a.m.-12:20 p.m.


Poster Session C / Exhibit Show
12:30-4 p.m.


Concurrent Sessions 7-9
4:15-6 p.m.

Concurrent Session 7: Antibody Drug Conjugates / Biotherapeutics
Session Cochairs: Giuseppe Curigliano, University of Milan, Milan, Italy, and Robert J. Kreitman, National Cancer Institute, Bethesda, Maryland

Antibody Drug Conjugates in solid tumors: The model of breast cancer
Giuseppe Curigliano

Title to be announced
Mitchell Ho, National Cancer Institute, Bethesda, Maryland

Recombinant immunotoxins for hematologic malignancies
Robert J. Kreitman

Panel Discussion

Concurrent Session 8: Cytokines
Session Cochairs: Claudia M. Palena, National Cancer Institute, Bethesda, Maryland, and Joan Seoane, Vall d’Hebron Institute of Oncology, Barcelona, Spain

IL-8 in tumor progression
Claudia M. Palena

BMP signaling in glioblastoma
Kohei Miyazono, University Tokyo, Tokyo, Japan

LIF in cancer
Joan Seoane

Panel Discussion

Concurrent Session 9: Emergent Themes from the Study of Resistance to Targeted Therapeutics
Session Cochairs: Ahmad Awada, Institut Jules Bordet, Brussels, Belgium, and Christina Curtis, Stanford University, Stanford, California

Lessons learnt in clinic from resistance to first generation molecular targeted therapies in solid cancers
Ahmad Awada

Early lessons from initial acquired resistance to TRK inhibitors
David M. Hyman, Memorial Sloan Kettering Cancer Center, New York, New York

Clonal dynamics and treatment associated changes in the tumor and immune microenvironment during neoadjuvant targeted therapy in HER2-positive breast cancer
Christina Curtis

Panel Discussion


Evening Off / Dinner on Own
6 p.m.




Wednesday, Oct. 30, 2019

Continental Breakfast
7-8 a.m.


Plenary Session 7: Big Data / Real-World Evidence, and Digital Health Opportunities
Session Cochairs: Bissan Al-Lazikani, The Institute of Cancer Research, London, United Kingdom, and Sean Khozin, U.S. Food & Drug Administration, Silver Spring, Maryland
8-9:45 a.m.

Introduction
Bissan Al-Lazikani

Title to be announced
Sean Khozin

Title to be announced
Bissan Al-Lazikani

Additional speaker to be announced

Panel Discussion


Break
9:45-10 a.m.


Plenary Session 8: Rational Approaches to the Discovery and Testing of Combination Therapies
Session Cochairs: Alberto Bardelli, University of Turin School of Medicine, Candiolo Cancer Institute IRCCS, Candiolo, Italy, and Peter K. Sorger, Harvard Medical School, Boston, Massachusetts
10-11:45 a.m.

Title to be announced
Jennifer L. Guerriero, Dana-Farber Cancer Institute, Boston, Massachusetts

Adaptive cancer mutability in response to targeted therapies
Alberto Bardelli

Mechanisms of combination therapy in cell and patient populations
Peter K. Sorger

Panel Discussion


Closing Remarks
11:45 a.m.-12 p.m.


Departure
12 p.m.